Hereditary Angioedema Treatment Market Competitive Landscape, Growth, and Forecast 2032
Hereditary Angioedema Treatment Market Competitive Landscape, Growth, and Forecast 2032
The hereditary angioedema (HAE) treatment market focuses on therapies designed to manage and prevent attacks of hereditary angioedema, a rare genetic disorder characterized by recurrent swelling in various parts of the body, including the skin, gastrointestinal tract, and airways. Treatments include C1 esterase inhibitor (C1-INH) therapies, kallikrein inhibitors, bradykinin B2 receptor antagonists, and novel biologics aimed at reducing the frequency and severity of HAE attacks. Market growth is driven by increasing disease awareness, improved diagnostic rates, and advancements in targeted therapies offering better efficacy and safety profiles. The introduction of subcutaneous and oral therapies has significantly enhanced patient convenience and adherence. Ongoing R&D efforts are also focusing on gene therapies and long-acting biologics to provide sustained disease control.
According to Fortune Business Insights, the global hereditary angioedema treatment market size was valued at USD 5.59 billion in 2024 and is projected to grow from USD 6.53 billion in 2025 to USD 19.68 billion by 2032, exhibiting a CAGR of 17.1% during the forecast period (2025–2032). North America dominated the market with a share of 93.05% in 2024.
CSL Behring
Shire plc.
Pharming Group NV
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Attune Pharmaceuticals
Arrowhead Pharmaceuticals, Inc.
Adverum Biotechnologies
Other prominent players
Leading companies are focusing on expanding their product portfolios, improving accessibility, and developing cost-effective therapies. CSL Behring, Shire, and Pharming Group NV hold a strong presence in the market through well-established brands and global distribution networks.
Rising prevalence of hereditary angioedema (HAE) and improved patient diagnosis rates.
Growing awareness about rare diseases and advancements in genetic testing technologies.
Strong adoption of preventive (prophylaxis) treatments reducing frequency and severity of attacks.
Introduction of innovative drug classes such as C1-esterase inhibitors, bradykinin receptor antagonists, and kallikrein inhibitors.
High treatment costs, especially for biologic and specialty drugs.
Limited awareness and diagnostic infrastructure in emerging regions.
Stringent regulatory approval processes for novel therapies.
Market size and forecast data from 2025 to 2032.
Comprehensive segmentation based on drug class, application, route of administration, and distribution channel.
Regional insights across North America, Europe, and the Rest of the World.
Competitive analysis of leading and emerging players.
Pipeline assessment and key product launches.
In August 2018, Shire announced U.S. FDA approval for TAKHZYRO as a preventive treatment for hereditary angioedema, marking a major milestone in the prophylactic therapy landscape.
The hereditary angioedema treatment market is moderately consolidated, with key players focusing on strategic collaborations, product development, and market expansion. Companies like CSL Behring, Shire plc, and Pharming Group NV dominate the market due to strong product portfolios and extensive clinical research. Meanwhile, BioCryst Pharmaceuticals, Ionis Pharmaceuticals, Attune Pharmaceuticals, Arrowhead Pharmaceuticals, and Adverum Biotechnologies are strengthening their market presence through innovation and pipeline development.
C1-Esterase Inhibitors: The largest segment, accounting for over 60% of global revenue in 2024.
Bradykinin Receptor Antagonists: Showing steady growth due to clinical efficacy and new product launches.
Kallikrein Inhibitors: Expected to record the fastest growth rate owing to novel formulations.
Prophylaxis: The fastest-growing segment, driven by the increasing focus on preventive care.
On-Demand (Acute) Treatment: Continues to be essential for managing severe attacks.
Intravenous (IV)
Subcutaneous
Hospital Pharmacies
Retail Pharmacies
Others
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/industry-reports/hereditary-angioedema-treatment-market-100164
North America held the largest market share in 2024, accounting for over 93% of the total revenue. The region’s dominance is attributed to advanced healthcare infrastructure, strong reimbursement policies, and early adoption of innovative therapies.
Europe followed as the second-largest region, driven by increasing diagnosis rates, clinical trials, and growing access to preventive treatments. However, high therapy costs and reimbursement constraints pose challenges.
Rest of the World regions such as Asia Pacific, Latin America, and the Middle East & Africa are expected to witness steady growth due to rising awareness, expanding healthcare systems, and new product approvals.
The hereditary angioedema treatment market is projected to expand substantially by 2032, fueled by technological advancements and the emergence of next-generation therapies. The growing shift toward gene-based and subcutaneous therapies is expected to improve patient convenience and compliance.
Development of cost-effective and patient-friendly therapies.
Entry of new market participants enhancing competition and innovation.
Increased government initiatives and funding for rare disease research.
Greater adoption of long-term prophylactic treatments among diagnosed patients.
While high drug costs and limited access in low-income countries remain barriers, the increasing focus on awareness programs and genetic screening initiatives is expected to create new growth opportunities worldwide.
The global hereditary angioedema treatment market is poised for robust expansion through 2032. Strong demand for preventive therapies, coupled with ongoing clinical developments and rising awareness, will continue to drive growth. With leading players such as CSL Behring, Shire plc, and Pharming Group NV shaping innovation and expanding patient reach, the future outlook remains highly positive. The focus on advanced biologics, cost optimization, and global market access will be key to sustaining this momentum in the coming years.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com